Myosin Therapeutics Inc SBIR Phase II award

Department of Health and Human Services, through National Institutes of Health, awarded Myosin Therapeutics Inc of Jupiter, FL $1,496,586 under the SBIR program (Phase II), with work starting 2025-04-01 and running to 2028-02-28. It is one of 2 SBIR and STTR awards Myosin Therapeutics Inc received in the last two years, $1,746,003 in all. Each figure links to the federal record.

The award

Want the whole picture on Myosin Therapeutics Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Myosin Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Myosin Therapeutics Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What it is for

Phase 0/1B clinical trial of novel therapeutic agent MT-110 for the reduction of methamphetamine use - part 2 - project summary as of 2023, close to 2 million individuals in the united states are identified as having met

Funding actions on this award

Phase 0/1B clinical trial of novel therapeutic agent MT-110 for the reduction of methamphetamine use - part 2 - project summary as of 2023, close to 2 million individuals in the united states are identified as having methamphetamine use disorder (mud), with methamphetamine use rising significantly. Recent estimates suggest that this figure is underreported by about 225%, bringing the 2023 total closer to over 4 million people with mud, and likely even higher in 2024. Mud is a persistent condition for which there are no fda-approved medications at present. The current treatments available are behavioral modification therapies, which show limited success, as indicated by high relapse rates (60-90%). This underscores the need for an additional pharmacotherapy that targets relapse triggers to help maintain abstinence. Comprehensive prior studies by our group and others have shown that relapse induced by drug-use reminders (or “triggers”) exerts a strong motivational influence, posing a lifelong relapse risk regardless of the duration of abstinence. Myosin therapeutics is developing MT-110, a drug marked by the novel therapeutic target of the molecular motor nonmuscle myosin ii (nmii). Preclinical research has demonstrated that a single acute inhibition of nmii activity can produce a highly specific, long-lasting effect by restoring the brain’s structural plasticity to a pre-methamp ...

From the federal award record.

Other SBIR and STTR awards to Myosin Therapeutics Inc

Where this comes from

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.

Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.

All SBIR and STTR awards